Subscribe to AIM at Melanoma Foundation’s news feed.
Click on “Follow” and decide if you want to get news from AIM at Melanoma Foundation via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to AIM at Melanoma Foundation comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from AIM at Melanoma Foundation which you are really interested in. Click on the blue “Filter” button below to get started.
Website title: AIM at Melanoma - Reshaping the Future Together - AIM at Melanoma Foundation
Is this your feed? Claim it!
A recent feature in allure magazine explores a concerning trend: The resurgence of tanning culture among younger generations.
The article examines how social media, beauty standards, and evolving attitudes toward appearance are influencing some consumers, especially young people, to embrace tanning despite decades of public health messaging about the danger...
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative communications with the U.S. Food and Drug Administration (FDA), the Company and the FDA have aligned on a path forw...
by Mara Klecker
Donna Altes was in her late 70s when she received her melanoma diagnosis, which came after a long stretch of uncertainty and misdiagnoses. What began as a small growth on her heel was removed multiple times – involving painful surgeries that made it hard to walk – only to return again. Finally, a biopsy proved it was far more serious than a ...
Each year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together leading cancer researchers and physicians from around the world to share the latest advances in cancer treatment, research, and patient care. For the melanoma community, ASCO often offers an important look at emerging therapies, evolving standards of care, clinical trial updates, and th...